We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integra (IART) Up 1.8% Since Earnings Report: Can It Continue?
Read MoreHide Full Article
About a month has gone by since the last earnings report for Integra LifeSciences Holdings Corporation (IART - Free Report) . Shares have added about 1.8% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Recent Earnings
Integra LifeSciences reported adjusted earnings per share of 45 cents in the third quarter of 2017, which declined 2.2% from the year-ago figure.
Adjusted EPS also missed the Zacks Consensus Estimate of 47 cents. Including one-time items, the company reported earnings of 4 cents per share, down 54% from the year-ago quarter.
Revenue Discussion
Total revenue in the reported quarter increased 11.4% year over year to $278.8 million, which lagged the Zacks Consensus Estimate of $286 million. Excluding revenues from acquisitions, discontinued products and the effect of currency exchange rates, organic revenues rose 1.5% year over year.
The solid revenue growth in the third quarter was primarily driven by strong contribution from the Orthopedics and Tissue Technologies segments. Coming to product categories, revenues from the company's Specialty Surgical Solutions segment increased 3.4% to $164.8 million.
Orthopedics and Tissue Technologies revenues came in at $114.1 million in the third quarter, up 25.5% year over year.
Margin Trend
Gross margin contracted 81 basis points (bps) to 63.5% in the reported quarter. Per the company, adjusted gross margin contracted 60 bps to 68.7%.
Selling, general and administrative expenses increased 29.9% to $145.9 million in the reported quarter, while research and development expenses contracted 0.6% to $15 million. Adjusted operating margin saw a 763-bps contraction to 5.8% in the third quarter.
Financial Position
Integra LifeSciences exited third-quarter 2017 with cash and cash equivalents of $481.9 million, up from $154.6 million recorded at the end of second-quarter 2017. As of Sep 30, 2017, net cash flow from operating activities was $102.9 million, down from $109.9 million in the year-ago quarter.
2017 Outlook Tweaked
Management has raised the full-year 2017 revenue guidance from $1.125-$1.140 billion to $1.165-$1.175 billion. Meanwhile, full-year 2017 organic revenue growth range was lowered to 4% from 6% to 7%. The Zacks Consensus Estimate for full-year 2017 revenues is $1.20 billion, below the guided range.
The company has revised its full-year 2017 adjusted EPS guidance to$1.83-$1.87 from the previous range of $1.88-$1.94. The Zacks Consensus Estimate for 2017 adjusted earnings is pegged at $1.91, above the company’s guided range.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimate flatlined during the past month. There has been one revision higher for the current quarter compared to one lower.
VGM Scores
Currently, Integra's stock has a nice Growth Score of B, though it is lagging a lot on the momentum front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate that the stock is more suitable for growth investors than value investors.
Outlook
The stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Integra (IART) Up 1.8% Since Earnings Report: Can It Continue?
About a month has gone by since the last earnings report for Integra LifeSciences Holdings Corporation (IART - Free Report) . Shares have added about 1.8% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Recent Earnings
Integra LifeSciences reported adjusted earnings per share of 45 cents in the third quarter of 2017, which declined 2.2% from the year-ago figure.
Adjusted EPS also missed the Zacks Consensus Estimate of 47 cents. Including one-time items, the company reported earnings of 4 cents per share, down 54% from the year-ago quarter.
Revenue Discussion
Total revenue in the reported quarter increased 11.4% year over year to $278.8 million, which lagged the Zacks Consensus Estimate of $286 million. Excluding revenues from acquisitions, discontinued products and the effect of currency exchange rates, organic revenues rose 1.5% year over year.
The solid revenue growth in the third quarter was primarily driven by strong contribution from the Orthopedics and Tissue Technologies segments.
Coming to product categories, revenues from the company's Specialty Surgical Solutions segment increased 3.4% to $164.8 million.
Orthopedics and Tissue Technologies revenues came in at $114.1 million in the third quarter, up 25.5% year over year.
Margin Trend
Gross margin contracted 81 basis points (bps) to 63.5% in the reported quarter. Per the company, adjusted gross margin contracted 60 bps to 68.7%.
Selling, general and administrative expenses increased 29.9% to $145.9 million in the reported quarter, while research and development expenses contracted 0.6% to $15 million. Adjusted operating margin saw a 763-bps contraction to 5.8% in the third quarter.
Financial Position
Integra LifeSciences exited third-quarter 2017 with cash and cash equivalents of $481.9 million, up from $154.6 million recorded at the end of second-quarter 2017. As of Sep 30, 2017, net cash flow from operating activities was $102.9 million, down from $109.9 million in the year-ago quarter.
2017 Outlook Tweaked
Management has raised the full-year 2017 revenue guidance from $1.125-$1.140 billion to $1.165-$1.175 billion. Meanwhile, full-year 2017 organic revenue growth range was lowered to 4% from 6% to 7%. The Zacks Consensus Estimate for full-year 2017 revenues is $1.20 billion, below the guided range.
The company has revised its full-year 2017 adjusted EPS guidance to$1.83-$1.87 from the previous range of $1.88-$1.94. The Zacks Consensus Estimate for 2017 adjusted earnings is pegged at $1.91, above the company’s guided range.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimate flatlined during the past month. There has been one revision higher for the current quarter compared to one lower.
VGM Scores
Currently, Integra's stock has a nice Growth Score of B, though it is lagging a lot on the momentum front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate that the stock is more suitable for growth investors than value investors.
Outlook
The stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.